The clinical trial of iPS cell therapy for Parkinson's disease at Xuanwu Hospital, Capital Medical University, has been initiated
2025-09-01
With the acceleration of global population aging, Parkinson's disease has become the second most common neurodegenerative disorder after Alzheimer's disease, affecting the health and quality of life of over ten million people worldwide.